Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Dr. Chil-Yong (Yong) Kang received his Ph.D. from McMaster University in Canada in 1971 and his D.Sc. degrees from McMaster University and from Carleton University. He took his three year postdoctoral training at the University of Wisconsin, Madison, USA. He has served as a Professor of Microbiology at the University of Texas, Southwestern Medical School in Dallas, Professor and Chairman of the Department of Microbiology and Immunology at University of Ottawa, Faculty of Medicine, Dean of Science at the University of Western Ontario, and currently is serving as Professor of Virology in the Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry at the University of Western Ontario. His research in molecular virology includes the development of antiviral therapeutic agents and efficacious vaccines against various human viral diseases. He has published 297 scientific papers in fields of virology, medicine, and molecular biology. He holds nine international patents. Dr. Kang has received numerous prizes including Ho-Am Prize in Medicine in 1999 and Queen Elizabeth II Diamond Jubilee Medal of the Governor General of Canada in 2012. Dr. Kang is an elected Life-time Fellow of the Royal Society of Canada, Academy of Science and an elected Life-time Member of the Korean Academy of Science and Technology.
His research in molecular virology includes the development of viral-specific antiviral therapeutic agents and efficacious vaccines against various human viral diseases including AIDS, hepatitis and hemorrhagic fever with renal syndrome. Previously, he developed a second generation vaccine against hepatitis B virus and an experimental vaccine against HIV/AIDS by using state-of-the-art technologies of genetic engineering and biotechnology. Recently, his Phase I human clinical trial of SAV001 prophylactic HIV vaccine, based on genetically modified killed-whole HIV-1, was successfully completed and preparing for the Phase II trial. Dr. Kang has published 135 peer reviewed research papers and 149 scientific proceedings and abstracts in the fields of virology, Immunology, molecular biology, and medicine. He holds nine international biotechnology patents that cover over 70 countries.